Aidi Injection Combined with Chemotherapy for the Treatment of Advanced Non-small Cell Lung Cancer

Objective:To observe the Aidi injection combined with chemotherapy for the treatment of advanced non-small cell lung cancer(NSCLC) clinically.Method:Based on inclusion criteria,98 cases of NSCLC were randomly divided into observation group and the control group(n=49 each).Two groups were given TP chemotherapy:TAX(docetaxel) 65 mg/m2,gtt 30-60 min,d0;DDP(cisplatin) 25-30 mg/m2,gtt,d1-d3.While the observation group was treated with Aidi injection 80～100 mL,adding 0.9% saline 400 mL gtt,a total of 14 d.Three weeks for both groups were lasted as a treatment cycle,2 treatment cycles were used to evaluate the clinical efficacy and survival in patients with and without the occurrence of side effects.Result:The total effective rate was 91.84%,77.55% in the two groups with significant difference(P0.05).The quality of life in the observation group was higher compared with that in the control group significantly(P0.05).CD3+,CD4+,CD4+ /CD8+,NK cells observed before and after treatment the difference was significant(P0.05);CD4+,CD4+/CD8+,NK cells after treatment between the two groups was statistically significant(P0.05).Two groups in bone marrow toxicity,peripheral neurotoxicity,vomiting and other side effects were statistically different(P0.05).Conclusion:Aidi injection combined with chemotherapy in the treatment of clinical NSCLC shows significant effect.It can improve the quality of life,enhance immunity,reduce the chemotherapy-induced toxicity.